Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports

Pin-Liang Zhang, Zeng-Jun Liu, Pin-Liang Zhang, Zeng-Jun Liu

Abstract

Rationale: Anlotinib, a novel orally administered multitargeted tyrosine kinase inhibitor, inhibiting tumor angiogenesis and growth, significantly prolonged overall survival, and progression-free survival with a manageable safety profile as a third-line therapy among refractory advanced nonsmall cell lung cancer (NSCLC) patients in ALTER 0303 trail (NCT02388919).

Patient concerns: Two squamous cell lung cancer patients with mediastinal metastasis undergoing the treatment of anlotinib developed clinical symptom of cough, which was worse upon ingestion.

Diagnoses: On the basis of patients' clinical symptoms and radiographic findings, they were diagnosed with acquired esophago-tracheobronchial fistula.

Interventions: We treated them with fully covered self-expandable metallic stents.

Outcomes: The clinical symptom of cough was immediately relieved after palliative treatment. Both patients elected to discontinue anlotinib treatment.

Lessons: These 2 cases imply that a close follow-up schedule for esophago-tracheobronchial fistula should be established when squamous cell lung cancer patients with mediastinal metastasis are undergoing anlotinib therapy. Early detection and adequate treatment are essential for patient symptom relief and survival.

Figures

Figure 1
Figure 1
Chest computed tomography (CT) scan showed mediastinal and left hilar mass, along with left total lung atelectasis (A). Left total lung atelectasis disappeared, however, acquired esophago-tracheobronchial fistula (thin arrow) occurred after anlotinib treatment (B). A fully covered self-expandable metallic stent was placed immediately after the diagnosis (C,D).
Figure 2
Figure 2
Chest computed tomography (CT) scan showed subcarinal lymph node metastasis (thick arrow) shrunk greatly after anlotinib treatment, however, acquired esophago-tracheobronchial fistula (thin arrow) occurred (B,C). A fully covered self-expandable metallic stent was placed immediately after the diagnosis (C,D).

References

    1. Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol 2018;4:1569–75.
    1. Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer 2018;118:654–61.
    1. Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 2018;109:1207–19.
    1. Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 2016;9:105.
    1. Cheng Y, Han BH, Li K, et al. Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts). J clin oncol 2018;36suppl:9080.
    1. Clagett OT, Payne JH, Moersch HJ. Acquired esophagotracheobronchial fistula. Surg Gynecol Obstet 1946;82:87–90.
    1. Buemi L, Stefanelli S, Bichard P, et al. Esophageal pulmonary fistula − a rare complication of radiation therapy: a case report. J Med Case Rep 2018;12:116.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅